High-grade prostate cancer and the prostate cancer prevention trial.
Logothetis
Christopher J
CJ
Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. clogothe@mdanderson.org
Schellhammer
Paul F
PF
D058891:5-alpha Reductase Inhibitors; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
D058891:5-alpha Reductase Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D018120:Finasteride